Developing transformative biotherapeutics based on follistatin for diseases of major unmet need
Slide 1 Text

Learn more

PB01: a first-in-class antagonist of the TGFβ superfamily
Slide 2 Text

Learn more

Targeting inflammatory, fibrotic and metabolic diseases
Slide 3 Text

Learn more

Therapy

PB01 (recombinant human follistatin-288) is a novel inhibitor of the TGFβ superfamily of cytokines, with potent anti-inflammatory and anti-fibrotic actions

Indications

Paranta is focused on developing PB01 for the treatment of cystic fibrosis lung disease and chronic kidney disease

Pipeline & Clinical Trials

Paranta is a clinical stage biopharmaceutical company with additional promising preclinical programs

about paranta biosciences

Paranta Biosciences is a clinical-stage biopharmaceutical company developing potentially transformative first-in-class biotherapeutics based on PB01, a unique form of recombinant human follistatin, targeting inflammatory, fibrotic and metabolic diseases with significant unmet medical need

about paranta biosciences

Paranta Biosciences is a clinical-stage biopharmaceutical company developing potentially transformative first-in-class biotherapeutics based on PB01, a unique form of recombinant human follistatin, targeting inflammatory, fibrotic and metabolic diseases with significant unmet medical need

Pipeline focused on inflammatory, fibrotic and metabolic diseases with high unmet need

Paranta is developing an inhaled form of PB01 for the treatment of CF lung disease. PB01 targets lung inflammation, fibrosis and mucus production and therefore has the potential to slow the progression of lung disease and preserve lung function in people living with CF. Despite the recent expansion in treatment options for CF with the introduction of medicines targeting specific CF mutations, there still remains a significant need for medicines which target the underlying lung inflammation and resulting lung remodelling.

Paranta is developing an injectable form of PB01 for use in the treatment of chronic kidney disease, including diabetic nephropathy. Kidney disease is a major comorbidity of diabetes affecting >150 million diabetic patients worldwide. Current treatment options for diabetic nephropathy, a form of chronic kidney disease, are only partially effective with limited ability to delay disease progression. Research conducted by McMaster University has shown the therapeutic potential of PB01 in a preclinical mouse model of diabetic kidney disease and fibrosis.

Management Team

Our management team is comprised of industry experts with significant research expertise, together with biotechnology & pharmaceutical experience.


Learn more

Directors

Paranta's Board of Directors includes a diverse group of professionals with corporate and investment banking experience, scientific and medical research expertise, and biotechnology experience.

Learn more

Investors

Paranta is an Australian unlisted, public company focused on developing transformative biotherapeutics based on follistatin that target diseases of major unmet need.

Learn more

Latest News

Read More

Share Price Information

Mkt Cap:
The Market is currently
Price Delay ~20min
Read More

Box 3 Title

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo.

Read More